167 related articles for article (PubMed ID: 29130688)
21. Predictive QSAR modeling of phosphodiesterase 4 inhibitors.
Kovalishyn V; Tanchuk V; Charochkina L; Semenuta I; Prokopenko V
J Mol Graph Model; 2012 Feb; 32():32-8. PubMed ID: 22023934
[TBL] [Abstract][Full Text] [Related]
22. Speeding up Early Drug Discovery in Antiviral Research: A Fragment-Based in Silico Approach for the Design of Virtual Anti-Hepatitis C Leads.
Speck-Planche A; Dias Soeiro Cordeiro MN
ACS Comb Sci; 2017 Aug; 19(8):501-512. PubMed ID: 28437091
[TBL] [Abstract][Full Text] [Related]
23. TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases.
Luan F; Cordeiro MN; Alonso N; García-Mera X; Caamaño O; Romero-Duran FJ; Yañez M; González-Díaz H
Bioorg Med Chem; 2013 Apr; 21(7):1870-9. PubMed ID: 23415089
[TBL] [Abstract][Full Text] [Related]
24. A quantitative structure-activity relationship (QSAR) analysis of the effects of aromatic substitution on the anticonvulsant activity and toxicity of arylsuccinimides.
Lange J; Kaźmierski W; Daroszewski J
Pol J Pharmacol Pharm; 1991; 43(1):71-7. PubMed ID: 1771166
[TBL] [Abstract][Full Text] [Related]
25. Towards cheminformatics-based estimation of drug therapeutic index: Predicting the protective index of anticonvulsants using a new quantitative structure-index relationship approach.
Chen S; Zhang P; Liu X; Qin C; Tao L; Zhang C; Yang SY; Chen YZ; Chui WK
J Mol Graph Model; 2016 Jun; 67():102-10. PubMed ID: 27262528
[TBL] [Abstract][Full Text] [Related]
26. Fragment-similarity-based QSAR (FS-QSAR) algorithm for ligand biological activity predictions.
Myint KZ; Ma C; Wang L; Xie XQ
SAR QSAR Environ Res; 2011 Jun; 22(3):385-410. PubMed ID: 21598200
[TBL] [Abstract][Full Text] [Related]
27. Modeling the activity of furin inhibitors using artificial neural network.
Worachartcheewan A; Nantasenamat C; Naenna T; Isarankura-Na-Ayudhya C; Prachayasittikul V
Eur J Med Chem; 2009 Apr; 44(4):1664-73. PubMed ID: 18977558
[TBL] [Abstract][Full Text] [Related]
28. A general ANN-based multitasking model for the discovery of potent and safer antibacterial agents.
Speck-Planche A; Cordeiro MN
Methods Mol Biol; 2015; 1260():45-64. PubMed ID: 25502375
[TBL] [Abstract][Full Text] [Related]
29. NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum.
González-Díaz H; Prado-Prado F; Sobarzo-Sánchez E; Haddad M; Maurel Chevalley S; Valentin A; Quetin-Leclercq J; Dea-Ayuela MA; Teresa Gomez-Muños M; Munteanu CR; José Torres-Labandeira J; García-Mera X; Tapia RA; Ubeira FM
J Theor Biol; 2011 May; 276(1):229-49. PubMed ID: 21277861
[TBL] [Abstract][Full Text] [Related]
30. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors.
Viña D; Uriarte E; Orallo F; González-Díaz H
Mol Pharm; 2009; 6(3):825-35. PubMed ID: 19281186
[TBL] [Abstract][Full Text] [Related]
31. 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE.
Prado-Prado F; García-Mera X; Escobar M; Alonso N; Caamaño O; Yañez M; González-Díaz H
Curr Top Med Chem; 2012; 12(16):1843-65. PubMed ID: 23030618
[TBL] [Abstract][Full Text] [Related]
32. Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs.
Prado-Prado FJ; Uriarte E; Borges F; González-Díaz H
Eur J Med Chem; 2009 Nov; 44(11):4516-21. PubMed ID: 19631422
[TBL] [Abstract][Full Text] [Related]
33. QSAR modeling of anti-invasive activity of organic compounds using structural descriptors.
Katritzky AR; Kuanar M; Dobchev DA; Vanhoecke BW; Karelson M; Parmar VS; Stevens CV; Bracke ME
Bioorg Med Chem; 2006 Oct; 14(20):6933-9. PubMed ID: 16908166
[TBL] [Abstract][Full Text] [Related]
34. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
[TBL] [Abstract][Full Text] [Related]
35. Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?
Dobchev D; Karelson M
Expert Opin Drug Discov; 2016 Jul; 11(7):627-39. PubMed ID: 27149299
[TBL] [Abstract][Full Text] [Related]
36. MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.
González-Díaz H; Prado-Prado F; García-Mera X; Alonso N; Abeijón P; Caamaño O; Yáñez M; Munteanu CR; Pazos A; Dea-Ayuela MA; Gómez-Muñoz MT; Garijo MM; Sansano J; Ubeira FM
J Proteome Res; 2011 Apr; 10(4):1698-718. PubMed ID: 21184613
[TBL] [Abstract][Full Text] [Related]
37. QSAR studies in the discovery of novel type-II diabetic therapies.
Abuhammad A; Taha MO
Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
[TBL] [Abstract][Full Text] [Related]
38. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
Shen M; Béguin C; Golbraikh A; Stables JP; Kohn H; Tropsha A
J Med Chem; 2004 Apr; 47(9):2356-64. PubMed ID: 15084134
[TBL] [Abstract][Full Text] [Related]
39. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
Malik S; Ahuja P; Sahu K; Khan SA
Eur J Med Chem; 2014 Sep; 84():42-50. PubMed ID: 25014748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
